Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares conducted on June 6, 2025, and filed on June 9, 2025. The Company, a foreign private issuer, executed a share repurchase through its corporate stockbroker, Merrill Lynch International, pursuant to a non-discretionary agreement entered into on June 4, 2025.
Key Financial Metrics and Transaction Details
The filing details a specific buyback transaction rather than comprehensive financial statements. Key metrics for the June 6, 2025 transaction include:
- Shares Purchased: 342,461 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,504.00 GBp; highest price paid was 1,520.50 GBp.
- Average Price: Volume-weighted average price paid was 1,511.23 GBp.
- Trading Venue: All purchases occurred on the London Stock Exchange (XLON).
- Treasury Holdings: Following this purchase, the Company holds 219,222,679 ordinary shares in treasury.
- Shares in Issue: 4,096,060,232 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 5.35% of total voting rights.
Since the commencement of the current agreement on June 4, 2025, the Company has purchased a total of 1,088,296 ordinary shares. The filing does not provide data on revenue, profit, cash flow, margins, or debt levels.
Material Changes
The primary material change reported is the reduction of shares in issue and the increase in treasury shares resulting from the buyback program. The total number of voting rights attributable to treasury shares has increased to 5.35% following the June 6 transaction. No other material changes to the Company's financial condition or operations are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance or management commentary regarding future operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. These risks are referenced as being described in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2024 and its Q1 Results for 2025.
Investor Verification Checklist
- Verify the total remaining authorization under the Company's existing buyback program.
- Confirm the impact of the 5.35% treasury share holding on earnings per share (EPS) calculations.
- Review the referenced 2024 Form 20-F and 2025 Q1 Results for detailed risk factors and financial performance metrics not included in this filing.
- Monitor subsequent filings for updates on the buyback program's progress and total shares repurchased.